FDA releases Ariflo briefing documents

Deliberations at Friday's meeting of FDA's Pulmonary-Allergy Drugs Advisory Committee will focus on the clinical relevance of the efficacy demonstrated in trials of GlaxoSmithKline's Ariflo cilomilast, and on the adequacy of the safety database,

Read the full 347 word article

How to gain access

Continue reading with a
two-week free trial.